CHARLOTTE, N.C., Nov. 13 /PRNewswire-FirstCall/ -- MedCath
Corporation (NASDAQ:MDTH), a healthcare provider focused on high
acuity healthcare services, predominately the diagnosis and
treatment of cardiovascular disease, today announced its operating
results for its fourth fiscal quarter, which ended September 30,
2008. In addition, MedCath announced the completion of the
syndication of a new $160.0 million, three-year senior secured
credit facility. The credit facility consists of a $75.0 million
term loan and an $85.0 million revolver. Proceeds of the term loan
will be used to repurchase all of MedCath's outstanding 9.875%
Senior Notes, while the revolver will replace MedCath's existing
revolver. MedCath's EPS from continuing operations equaled $0.02 in
the fourth quarter of fiscal 2008. Strong cash flows during the
fourth quarter of fiscal 2008 resulted in MedCath's Adjusted Free
Cash Flows equaling $0.41 per diluted share. Fourth Quarter 2008
Results MedCath's reported net revenue increased 4.0% to $150.9
million in the fourth quarter of fiscal 2008 from $145.1 million in
the fourth quarter of fiscal 2007. Income from operations decreased
to $5.2 million from $14.4 million in the fourth quarter of fiscal
2007 and Adjusted EBITDA decreased to $12.5 million from $22.7
million in the same period of the prior year. MedCath's income from
continuing operations was $0.4 million, or $0.02 per diluted share,
in the fourth quarter of fiscal 2008 compared to $2.5 million, or
$0.11 per diluted share, in the fourth quarter of fiscal 2007.
MedCath's Adjusted EBITDA for the fourth quarter of fiscal 2008
includes the following significant items related to the resolution
of prior years' activities: -- A $0.9 million decrease in Adjusted
EBITDA related to settlement expense and legal cost of a
non-patient dispute between MedCath Partners and a hospital that
receives catheterization management services from a venture in
which MedCath Partners is the majority owner; and -- A $1.4 million
reduction in net revenue and Adjusted EBITDA related to prior
period cost reports and prior period cost report valuation
allowances, primarily related to Medicare. In addition, MedCath's
Adjusted EBITDA for the fourth quarter of fiscal 2008 reflects the
following significant items: -- A $3.0 million reduction in
Adjusted EBITDA in comparison to the third quarter of 2008 at two
hospitals that experienced a sequential decline in patient volumes;
-- A $2.0 million reduction in Adjusted EBITDA due to an increase
in reserves for doubtful accounts related to lower collection
percentage of certain patient accounts, most notably in the
collection of the self-pay portion of commercial insurance
contracts and in the collections from patients applying, but not
approved for, government assistance; and -- A $0.9 million
reduction in Adjusted EBITDA due to an increase in accounts
receivable allowance to reflect the expectation of lower
reimbursement for commercial non-contract ER business at one of our
hospitals. Adjusted EBITDA in this release does not include
share-based compensation or pre-opening expenses, but these items
are included as a component of income from continuing operations.
Share-based compensation expense provided a $0.5 million benefit in
the fourth quarter of fiscal 2008, or $0.01 per diluted share,
compared to a $0.5 million expense, or $0.01 per diluted share, in
the fourth quarter of fiscal 2007. Pre-opening expenses totaled
$0.1 million in the fourth quarter of fiscal 2008, compared to $0.6
million in the fourth quarter of fiscal 2007. "During the fourth
quarter we experienced an increase in drug-eluting stent and
certain surgery volumes," said Ed French, MedCath's President and
Chief Executive Officer. "Despite these improved volumes, we were
challenged by higher operating expense, especially uncompensated
care expense. As we look forward, we see continued near-term
challenges from current economic uncertainties and their impact on
surgeries that might be delayed and ultimate collections on
procedures performed." Capitalized interest totaled $1.1 million in
the fourth quarter primarily due to construction projects in
Kingman, Arizona and St. Tammany Parish, Louisiana. There was a
nominal amount of capitalized interest in the fourth quarter of
fiscal 2007. MedCath's annualized effective income tax rate
increased to 42.5% at its fiscal year end from 39.0% at its fiscal
third quarter of 2008. Operating Statistics, Cash Flow and Capital
Expenditures Same facility hospital admissions in the fourth
quarter of fiscal 2008 were 6,980, down 1.9% compared to the fourth
quarter of fiscal 2007. Total admissions through the emergency
department equaled 25.2% of admissions for the fourth quarter of
fiscal 2008 in comparison to 26.2% in the fourth quarter of fiscal
2007. Self-pay admissions equaled 2.5% of total admissions in the
fourth quarter of fiscal 2008, in comparison to 2.4% of total
admissions in the fourth quarter of fiscal 2007. Total
uncompensated care, which includes charity care plus bad debt
expense, equaled 10.4% of net revenue before the deduction for
charity care in the fourth quarter of fiscal 2008 compared to 7.4%
in the fourth quarter of fiscal 2007. Same facility hospital
outpatient visits totaled 7,542 in the fourth quarter of fiscal
2008, up 22.5% in comparison to the fourth quarter of fiscal 2007.
Adjusted admissions of 9,976 were up 3.7% in the fourth quarter of
fiscal 2008 in comparison to the fourth quarter of fiscal 2007. Net
cash provided by operating activities from continuing operations
for the fourth quarter of fiscal 2008 was $13.6 million, down from
$15.9 million for the fourth quarter of fiscal 2007. Cash capital
expenditures, including $21.4 million in expenditures related to
MedCath's growth initiatives, totaled $29.5 million in the fourth
quarter of fiscal 2008 in comparison to $17.8 million in the fourth
quarter of fiscal 2007. Bank Credit Facility MedCath also announced
today the completion of the syndication of a $160.0 million,
three-year senior secured credit facility. The syndication was
jointly led by Bank of America, N.A. as the administrative agent
and Wachovia Bank, National Association, as the syndication agent.
The credit facility consists of a $75.0 million term loan and an
$85.0 million revolver, and is secured with a lien on the assets of
MedCath and its wholly owned subsidiaries. The credit facility is
governed by customary financial and non-financial covenants and its
interest rate is subject to a pricing grid based on MedCath's total
leverage ratio. The initial pricing is at MedCath's option of
either the London Interbank Offered Rate (LIBOR) plus 300 bps, or
Bank of America's base rate, as defined in the agreement, plus 200
bps. MedCath will use the proceeds of the $75.0 million term loan,
along with cash on hand, to repurchase all of the Company's $102.0
million outstanding 9 7/8% senior notes, plus pay the notes'
repurchase premium of approximately $5.0 million. The $85.0 million
revolver replaces MedCath's current $100.0 million revolver and
will be available to support general corporate purposes. In
addition to the repurchase premium, MedCath will incur
approximately $2.0 million in expense in its first quarter of
fiscal 2009, ending December 31, 2008, related to the write-off of
previously incurred financing cost. "We are pleased to announce the
consummation of our new credit facility and notification of our
notes repurchase," said Jeff Hinton, MedCath's Chief Financial
Officer. "The facility represents a significant increase in bank
commitments despite unprecedented volatility in the credit markets.
The facility allows MedCath to significantly reduce borrowing
costs, fund previously announced growth capital requirements and
selectively pursue hospital acquisitions or limited share
repurchases." 2009 Guidance MedCath also announced today that due
to its development activities and diversification strategy, which
are expected to result in the opening of 150 inpatient beds over
the next 12 months, it is eliminating the previous practice of
providing annual financial guidance. The decision to end this
practice is based on management's belief that its actual
performance and the successful execution of its long-term strategy
are the best measures of the Company's value. Use of Non-GAAP
Financial Measures This release contains measures of MedCath's
historical financial performance that are not calculated and
presented in conformity with generally accepted accounting
principles ("GAAP"), including Adjusted EBITDA and Adjusted Free
Cash Flows. Adjusted EBITDA represents MedCath's income from
continuing operations before interest expense; interest and other
income, net; income tax expense; depreciation; amortization;
share-based compensation expense; pre-opening expenses; loss on
disposal of property, equipment and other assets; loss on early
extinguishment of debt; equity in net earnings of unconsolidated
affiliates; and minority interest share of earnings of consolidated
subsidiaries. Free Cash Flows is defined as cash flows from
continuing operations less non-expansion capital expenditures.
Management further adjusts the calculation of Free Cash Flows in
arriving at Adjusted Free Cash Flows by adjusting Free Cash Flows
to evenly disseminate interest payments paid twice a year.
MedCath's management uses Adjusted EBITDA to measure the
performance of the company's various operating entities, to compare
actual results to historical and budgeted results, and to make
capital allocation decisions. Management provides Adjusted EBITDA
to investors to assist them in performing their analyses of
MedCath's historical operating results. Further, management
believes that many investors in MedCath also invest in, or have
knowledge of, other healthcare companies that use Adjusted EBITDA
as a financial performance measure. Because Adjusted EBITDA is a
non- GAAP measure, Adjusted EBITDA, as defined above, may not be
comparable to other similarly titled measures of other companies.
MedCath has included a supplemental schedule with the financial
statements that accompanies this press release that reconciles
historical Adjusted EBITDA to MedCath's income from continuing
operations. Adjusted Free Cash Flow is utilized by management to
measure the quality of MedCath's earnings. Management will discuss
and answer questions regarding MedCath's quarterly results Friday,
November 14, 2008, during a 9 a.m. ET conference call. In the
United States, you may participate by dialing (877) 697-5351.
International callers should dial (706) 634-0602. The conference ID
for both domestic and international callers is 71798429. A live web
cast will also be available on the company's web site,
http://www.medcath.com/. This information will be available on the
web site on or immediately following the conference call for 30
days. A recorded replay of the call will be available until 11:59
p.m. ET, November 21, 2008. To access the replay, domestic callers
should dial (800) 642-1687 and international callers should dial
(706) 645-9291. The archived conference ID is 71798429. This press
release and the financial information included therewith will be
accessible on the web, by going to http://www.medcath.com/,
"Investor Relations," then clicking on "News." MedCath Corporation,
headquartered in Charlotte, N.C., is a healthcare provider focused
on high acuity services with the diagnosis and treatment of
cardiovascular disease being a primary service offering. MedCath
owns an interest in and operates nine hospitals with a total of 676
licensed beds, located in Arizona, Arkansas, California, Louisiana,
New Mexico, South Dakota, and Texas. MedCath is in the process of
developing its tenth hospital, which is anticipated to open in fall
2009, in Kingman, Ariz. In addition, MedCath and its subsidiary
MedCath Partners provide services in diagnostic and therapeutic
facilities in various states. Parts of this announcement contain
forward-looking statements that involve risks and uncertainties.
Although management believes that these forward- looking statements
are based on reasonable assumptions, these assumptions are
inherently subject to significant economic, regulatory and
competitive uncertainties and contingencies that are difficult or
impossible to predict accurately and are beyond our control
including, but not limited to, enactment of changes in federal law
that would limit physician hospital ownership. Actual results could
differ materially from those projected in these forward- looking
statements. We do not assume any obligation to update these
statements in a news release or otherwise should material facts or
circumstances change in ways that would affect their accuracy. The
preparation of MedCath's fourth quarter operating results requires
management to make estimates and assumptions that affect reported
amounts of revenues and expenses. There is a reasonable possibility
that actual results may vary significantly from those estimates.
These various risks and uncertainties are described in detail in
"Risk Factors" in MedCath's Annual Report or Form 10-K for the year
ended September 30, 2007 filed with the Securities and Exchange
Commission on December 14, 2007. Copies of this form including
exhibits are available on the internet site of the Securities and
Exchange Commission at http://www.sec.gov/. MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per
share data) (Unaudited) Three Months Ended Twelve Months Ended
September 30, September 30, 2008 2007 2008 2007 Net revenue
$150,921 $145,084 $613,955 $660,603 Operating expenses: Personnel
expense 50,163 47,200 201,685 209,501 Medical supplies expense
44,010 38,768 170,801 176,615 Bad debt expense 11,839 9,011 43,691
51,360 Other operating expenses 31,933 27,851 121,174 129,770
Pre-opening expenses 143 555 786 555 Depreciation 7,670 6,748
30,261 31,236 Amortization 149 126 560 631 (Gain) loss on disposal
of property, equipment and other assets (143) 420 248 1,447 Total
operating expenses 145,764 130,679 569,206 601,115 Income from
operations 5,157 14,405 44,749 59,488 Other income (expenses):
Interest expense (2,642) (3,916) (14,300) (22,068) Loss on early
extinguishment of debt - (223) - (9,931) Interest and other income,
net 100 1,568 2,043 7,843 Equity in net earnings of unconsolidated
affiliates 1,049 (2,922) 7,891 5,739 Total other expenses, net
(1,493) (5,493) (4,366) (18,417) Income from continuing operations
before minority interest and income taxes 3,664 8,912 40,383 41,071
Minority interest share of earnings of consolidated subsidiaries
(1,617) (4,437) (15,476) (13,917) Income from continuing operations
before income taxes 2,047 4,475 24,907 27,154 Income tax expense
1,670 2,022 10,587 11,903 Income from continuing operations 377
2,453 14,320 15,251 Income (loss) from discontinued operations, net
of taxes 344 (1,545) 6,922 (3,724) Net income $721 $908 $21,242
$11,527 Earnings (loss) per share, basic Continuing operations
$0.02 $0.11 $0.71 $0.73 Discontinued operations 0.02 (0.07) 0.35
(0.17) Earnings (loss) per share, basic $0.04 $0.04 $1.06 $0.56
Earnings (loss) per share, diluted Continuing operations $0.02
$0.11 $0.71 $0.71 Discontinued operations 0.02 (0.07) 0.35 (0.17)
Earnings (loss) per share, diluted $0.04 $0.04 $1.06 $0.54 Weighted
average number of shares, basic 19,590 21,202 19,996 20,872
Dilutive effect of stock options and restricted stock 65 579 73 639
Weighted average number of shares, diluted 19,655 21,781 20,069
21,511 MEDCATH CORPORATION CONSOLIDATED BALANCE SHEETS (In
thousands, except share data) September 30, September 30, 2008 2007
(Unaudited) Current assets: Cash and cash equivalents $94,174
$140,276 Restricted cash 3,154 - Accounts receivable, net 84,791
85,943 Income tax receivable 3,637 - Medical supplies 16,070 13,928
Deferred income tax assets 7,300 12,389 Prepaid expenses and other
current assets 9,893 6,197 Current assets of discontinued
operations 19,856 22,832 Total current assets 238,875 281,565
Property and equipment, net 323,780 270,663 Investments in
affiliates 15,285 5,718 Goodwill 60,049 62,740 Other intangible
assets, net 6,063 6,448 Other assets 8,379 6,531 Long-term assets
of discontinued operations - 44,902 Total assets $652,431 $678,567
Current liabilities: Accounts payable $41,739 $30,933 Income tax
payable - 10,552 Accrued compensation and benefits 16,885 18,567
Other accrued liabilities 23,663 13,421 Current portion of
long-term debt and obligations under capital leases 31,920 4,089
Current liabilities of discontinued operations 10,422 24,962 Total
current liabilities 124,629 102,524 Long-term debt 115,628 146,398
Obligations under capital leases 2,087 1,793 Deferred income tax
liabilities 10,339 12,018 Other long-term obligations 3,691 460
Long-term liabilities of discontinued components - 13 Total
liabilities 256,374 263,206 Minority interest in equity of
consolidated subsidiaries 24,543 29,737 Stockholders' equity:
Preferred stock, $0.01 par value, 10,000,000 shares authorized;
none issued - - Common stock, $0.01 par value, 50,000,000 shares
authorized; 21,553,054 issued and 19,598,693 outstanding at
September 30, 2008; 21,271,144 issued and 21,202,244 outstanding at
September 30, 2007 216 213 Paid-in capital 457,160 447,688
Accumulated deficit (40,886) (61,821) Accumulated other
comprehensive loss (179) (62) Treasury stock, at cost; 68,900
shares at September 30, 2007 1,954,361 shares at September 30, 2008
(44,797) (394) Total stockholders' equity 371,514 385,624 Total
liabilities and stockholders' equity $652,431 $678,567 MEDCATH
CORPORATION SELECTED OPERATING DATA (In thousands, except per share
data and selected operating data) (Unaudited) Three Months Ended
September 30, 2008 2007 % Change Statement of Operations Data: Net
revenue $150,921 $145,084 4.0% Adjusted EBITDA (1) $12,491 $22,743
(45.1)% Income from operations $5,157 $14,405 (64.2)% Income from
continuing operations $377 $2,453 (84.6)% Earnings per share from
continuing operations, basic $0.02 $0.11 (81.8)% Earnings per share
from continuing operations, diluted $0.02 $0.11 (81.8)% Twelve
Months Ended September 30, 2008 2007 % Change Statement of
Operations Data: Net revenue $613,955 $660,603 (7.1)% Adjusted
EBITDA (1) $81,582 $97,672 (16.5)% Income from operations $44,749
$59,488 (24.8)% Income from continuing operations $14,320 $15,251
(6.1)% Earnings per share from continuing operations, basic $0.71
$0.73 (2.7)% Earnings per share from continuing operations, diluted
$0.71 $0.71 - (1) See Supplemental Financial
Disclosure--Reconciliation of GAAP Financial Measures to Non-GAAP
Financial Measures. Three Months Ended September 30, 2008 2007 %
Change Selected Operating Data (a): Number of hospitals 7 7
Licensed beds ( c ) 509 421 Staffed and available beds ( d ) 464
404 Admissions ( e ) 6,980 7,118 (1.9)% Adjusted admissions ( f )
9,976 9,622 3.7% Patient days ( g ) 25,500 24,290 5.0% Adjusted
patient days ( h ) 36,776 33,011 11.4% Average length of stay
(days) ( i ) 3.65 3.41 7.0% Occupancy ( j ) 59.7% 65.4% Inpatient
catheterization procedures ( k ) 3,735 3,904 (4.3)% Inpatient
surgical procedures ( l ) 2,050 1,959 4.6% Hospital net revenue
$139,487 $133,215 4.7% Selected Operating Data - Same Facility (a):
Number of hospitals 7 7 Licensed beds ( c ) 509 421 Staffed and
available beds ( d ) 464 404 Admissions ( e ) 6,980 7,118 (1.9)%
Adjusted admissions ( f ) 9,976 9,622 3.7% Patient days ( g )
25,500 24,290 5.0% Adjusted patient days ( h ) 36,776 33,011 11.4%
Average length of stay (days) ( i ) 3.65 3.41 7.0% Occupancy ( j )
59.7% 65.4% Inpatient catheterization procedures ( k ) 3,735 3,904
(4.3)% Inpatient surgical procedures ( l ) 2,050 1,959 4.6%
Hospital net revenue $139,487 $133,215 4.7% Combined Operating Data
(b): Number of hospitals 9 9 Licensed beds ( c ) 676 588 Staffed
and available beds ( d ) 629 567 Admissions ( e ) 9,997 9,779 2.2%
Adjusted admissions ( f ) 14,791 13,678 8.1% Patient days ( g )
34,732 32,748 6.1% Adjusted patient days ( h ) 51,281 45,697 12.2%
Average length of stay (days) ( i ) 3.47 3.35 3.6% Occupancy ( j )
60.0% 62.8% Inpatient catheterization procedures ( k ) 4,524 4,719
(4.1)% Inpatient surgical procedures ( l ) 2,666 2,645 0.8%
Hospital net revenue $179,296 $171,074 4.8% Twelve Months Ended
September 30, 2008 2007 % Change Selected Operating Data (a):
Number of hospitals 7 7 Licensed beds ( c ) 509 421 Staffed and
available beds ( d ) 464 404 Admissions ( e ) 29,360 35,373 (17.0)%
Adjusted admissions ( f ) 40,971 48,306 (15.2)% Patient days ( g )
107,353 120,556 (11.0)% Adjusted patient days ( h ) 150,559 164,131
(8.3)% Average length of stay (days) ( i ) 3.66 3.41 7.3% Occupancy
( j ) 63.4% 81.8% Inpatient catheterization procedures ( k ) 15,979
17,925 (10.9)% Inpatient surgical procedures ( l ) 8,383 9,481
(11.6)% Hospital net revenue $565,787 $607,551 (6.9)% Selected
Operating Data - Same Facility (a): Number of hospitals 7 7
Licensed beds ( c ) 509 421 Staffed and available beds ( d ) 464
404 Admissions ( e ) 29,360 29,893 (1.8)% Adjusted admissions ( f )
40,971 39,375 4.1% Patient days ( g ) 107,353 104,684 2.5% Adjusted
patient days ( h ) 150,559 138,263 8.9% Average length of stay
(days) ( i ) 3.66 3.50 4.6% Occupancy ( j ) 63.4% 71.0% Inpatient
catheterization procedures ( k ) 15,979 17,299 (7.6)% Inpatient
surgical procedures ( l ) 8,383 8,039 4.3% Hospital net revenue
$565,787 $546,539 3.5% Combined Operating Data (b): Number of
hospitals 9 9 Licensed beds ( c ) 676 588 Staffed and available
beds ( d ) 629 567 Admissions ( e ) 40,176 40,871 (1.7)% Adjusted
admissions ( f ) 58,669 55,585 5.5% Patient days ( g ) 141,346
139,433 1.4% Adjusted patient days ( h ) 205,032 188,499 8.8%
Average length of stay (days) ( i ) 3.52 3.41 3.2% Occupancy ( j )
61.6% 67.4% Inpatient catheterization procedures ( k ) 19,148
20,557 (6.9)% Inpatient surgical procedures ( l ) 10,954 10,941
0.1% Hospital net revenue $725,188 $695,530 4.3% (a) Selected
operating data includes consolidated hospitals in operation as of
the end of the period reported in continuing operations but does
not include hospitals which are accounted for using the equity
method or as discontinued operations in our consolidated financial
statements. Same facility for all periods presented excludes
Harlingen Medical Center. (b) Combined operating data includes
hospitals in operation as of the end of the period reported in
continuing operations including hospitals which are accounted for
using the equity method in our consolidated financial statements.
(c) Licensed beds represent the number of beds for which the
appropriate state agency licenses a facility regardless of whether
the beds are actually available for patient use. (d) Staffed and
available beds represent the number of beds that are readily
available for patient use at the end of the period. (e) Admissions
represent the number of patients admitted for inpatient treatment.
(f) Adjusted admissions is a general measure of combined inpatient
and outpatient volume. We computed adjusted admissions by dividing
gross patient revenue by gross inpatient revenue and then
multiplying the quotient by admissions. (g) Patient days represent
the total number of days of care provided to inpatients. (h)
Adjusted patient days is a general measure of combined inpatient
and outpatient volume. We computed adjusted patient days by
dividing gross patient revenue by gross inpatient revenue and then
multiplying the quotient by patient days. (i) Average length of
stay (days) represents the average number of days inpatients stay
in our hospitals. (j) We computed occupancy by dividing patient
days by the number of days in the period and then dividing the
quotient by the number of staffed and available beds. (k)
Inpatients with a catheterization procedure represent the number of
inpatients with a procedure performed in one of the hospitals'
catheterization labs during the period. (l) Inpatient surgical
procedures represent the number of surgical procedures performed on
inpatients during the period. MEDCATH CORPORATION SUPPLEMENTAL
FINANCIAL DISCLOSURE - RECONCILIATION OF GAAP FINANCIAL MEASURES TO
NON-GAAP FINANCIAL MEASURES (Unaudited) The following table
reconciles Adjusted EBITDA with MedCath's income from continuing
operations as derived directly from MedCath's consolidated
financial statements for the three and twelve months ended
September 30, 2008 and 2007. Three Months Twelve Months Ended Ended
September 30, September 30, 2008 2007 2008 2007 (in thousands)
Income from continuing operations $377 $2,453 $14,320 $15,251 Add:
Income tax expense 1,670 2,022 10,587 11,903 Minority interest
share of earnings of consolidated subsidiaries 1,617 4,437 15,476
13,917 Equity in net earnings of unconsolidated affiliates (1,049)
2,922 (7,891) (5,739) Interest and other income, net (100) (1,568)
(2,043) (7,843) Loss on early extinguishment of debt - 223 - 9,931
Interest expense 2,642 3,916 14,300 22,068 (Gain) loss on disposal
of property, equipment and other assets (143) 420 248 1,447
Amortization 149 126 560 631 Depreciation 7,670 6,748 30,261 31,236
Pre-opening expenses 143 555 786 555 Share-based compensation
expense (485) 489 4,978 4,315 Adjusted EBITDA $12,491 $22,743
$81,582 $97,672 The following table presents MedCath's condensed
statement of operations data for the quarter and year ended
September 30, 2007 on a pro forma basis to reflect the
reclassification of Harlingen Medical Center (HMC) from a
consolidated subsidiary to an equity method investment. Three
Months Ended September 30, Adjustments to 2007 Deconsolidate 2007
(Actual) HMC (Pro Forma) 2008 (in thousands) Net Revenue $145,084
$- $145,084 $150,921 Income from operations 14,405 - 14,405 5,157
Income from continuing operations before minority interest and
income taxes 8,912 - 8,912 3,664 Income from continuing operations
before income taxes 4,475 - 4,475 2,047 Income from continuing
operations 2,453 - 2,453 377 Net income (loss) $908 $- $908 $721
Earnings (loss) per share, basic $0.04 $- $0.04 $0.04 Earnings
(loss) per share, diluted $0.04 $- $0.04 $0.04 Weighted average
number of shares, basic 21,202 - 21,202 19,590 Dilutive effect of
stock options and restricted stock 579 - 579 65 Weighted average
number of shares, diluted 21,781 - 21,781 19,655 Twelve Months
Ended September 30, Adjustments to 2007 Deconsolidate 2007 (Actual)
HMC (Pro Forma) 2008 (in thousands) Net Revenue $660,603 $(61,012)
$599,591 $613,955 Income from operations 59,488 (2,321) 57,167
44,749 Income from continuing operations before minority interest
and income taxes 41,071 1,191 42,262 40,383 Income from continuing
operations before income taxes 27,154 1,191 28,345 24,907 Income
from continuing operations 15,251 1,191 16,442 14,320 Net income
(loss) $11,527 $1,191 $12,718 $21,242 Earnings (loss) per share,
basic $0.56 $0.06 $0.62 $1.06 Earnings (loss) per share, diluted
$0.54 $0.06 $0.60 $1.06 Weighted average number of shares, basic
20,872 - 20,872 19,996 Dilutive effect of stock options and
restricted stock 639 - 639 73 Weighted average number of shares,
diluted 21,511 - 21,511 20,069 The following table reflects the
calculation of adjusted free cash flow and adjusted free cash flow
per diluted share. Free Cash Flows is commonly defined as cash
flows from continuing operations less capital expenditures.
Management further adjusts the calculation of Free Cash Flows in
arriving at Adjusted Free Cash Flows by adjusting Free Cash Flows
to evenly disseminate interest payments paid twice a year. Three
Months Ended September 30, 2008 Adjusted Free Cash Flow Per Share
Calculation (in thousands) Cash flow from continuing operations
$13,626 Adjustment for semi-annual coupon payment 2,517 Less:
Non-expansion capital expenditures (8,022) Adjusted free cash flow
$8,121 Diluted shares outstanding 19,655 Adjusted Free Cash Flow
per diluted share $0.41 DATASOURCE: MedCath Corporation CONTACT: O.
Edwin French, President-Chief Executive Officer, +1-704-708-6600,
or Jeff Hinton, Chief Financial Officer, +1-704-708-6600, both of
MedCath Corporation Web site: http://www.medcath.com/
Copyright
Medcath (NASDAQ:MDTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medcath (NASDAQ:MDTH)
Historical Stock Chart
From Jul 2023 to Jul 2024